Aimmune's peanut allergy treatment could 'change practice' — with safety challenges and a price anything but peanuts
Aimmune Therapeutics $AIMT has detailed the results of its Phase III study of its peanut allergy therapy known as AR101 in the New England Journal …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
